Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Venus Medtech (Hangzhou) Inc. (2500.HK)
Hangzhou, HK
Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat the patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Venus-Vitae, a balloon-expandable dry-tissue product; Venus-PowerX, a self-expanding dry-tissue product; Cardiovalve, a transcatheter valve replacement system for the treatment of patients with mitral regurgitation and in pivotal clinical trial for the treatment of patients with tricuspid regurgitation; Liwen RF, a radiofrequency ablation system for the treatment of hypertrophic cardiomyopathy; and renal artery denervation ablation system for the treatment of hypertension. In addition, the company offers procedural accessories comprising catheter sheath product and balloon catheter. Venus Medtech (Hangzhou) Inc. was incorporated in 2009 and is headquartered in Hangzhou, the People’s Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.63% | -6.92% | -33.88% | -56.16% | -50.21% | -49.16% | -51.41% | -84.20% | -98.31% | -97.19% | -97.19% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-02 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%-34.8% Q4'25: -49.3% (vs Q4'23)
-
EPS growth Medical - Specialties: +10.1%+42.9% ★ Q4'25: +23.5% (vs Q4'23)
-
FCF margin FCF growth · Medical - Specialties: +51.3%-135.9% Q4'25: -277.6% (vs Q4'23)
-
EBIT margin Medical - Specialties: +12.6%-112.6% Q4'25: -174.0% (vs Q4'23)
-
ROIC Medical - Specialties: +6.6%-20.3% Q4'25: -49.0% (vs Q4'23)
-
Share dilution Medical - Specialties: 0.0%+0.0% ★ Q4'25: +0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×-0.69× Q4'25: -0.26× (vs Q4'23)
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
233.27M
est: 261.91M (-10.9%)
|
276.05M
est: 371.11M (-25.6%)
|
415.86M
est: 554.05M (-24.9%)
|
406.46M
est: 488.67M (-16.8%)
|
491.37M
est: 566.97M (-13.3%)
|
470.83M
est: 567.44M (-17.0%)
|
306.79M
est: 723.69M (-57.6%)
|
821.18M
821.18M – 821.18M
+13.5% YoY
|
3.71B
3.71B – 3.71B
+351.7% YoY
|
| EBITDA |
-343.62M
est: -226.96M (-51.4%)
|
-152.83M
est: -516.23M (+70.4%)
|
-324.03M
est: -1.30B (+75.1%)
|
-999.37M
est: -2.43B (+58.9%)
|
-547.84M
est: -5.20B (+89.5%)
|
-612.96M
est: -542.38M (-13.0%)
|
-315.42M
est: -691.73M (+54.4%)
|
-784.92M
-784.92M – -784.92M
-13.5% YoY
|
-3.55B
-3.55B – -3.55B
-351.7% YoY
|
| EBIT |
-372.53M
est: -238.35M (-56.3%)
|
-178.56M
est: -513.39M (+65.2%)
|
-375.65M
est: -1.29B (+70.9%)
|
-1.11B
est: -2.42B (+54.0%)
|
-672.62M
est: -5.17B (+87.0%)
|
-724.07M
est: -12.19B (+94.1%)
|
-345.32M
est: -709.70M (+51.3%)
|
-805.30M
-805.30M – -805.30M
-13.5% YoY
|
-3.64B
-3.64B – -3.64B
-351.7% YoY
|
| Net Income |
-380.77M
est: -296.45M (-28.4%)
|
-182.87M
est: -543.52M (+66.4%)
|
-373.64M
est: -1.37B (+72.7%)
|
-1.06B
est: -1.21B (+12.4%)
|
-703.75M
est: -569.81M (-23.5%)
|
-714.31M
est: -586.17M (-21.9%)
|
-407.69M
est: -284.52M (-43.3%)
|
-113.54M
-113.54M – -113.54M
+60.1% YoY
|
25.17M
25.17M – 25.17M
+122.2% YoY
|
| SGA |
322.18M
est: 238.96M (+34.8%)
|
238.64M
est: 338.58M (-29.5%)
|
344.65M
est: 505.49M (-31.8%)
|
452.56M
est: 445.84M (+1.5%)
|
454.26M
est: 517.28M (-12.2%)
|
391.09M
est: 527.70M (-25.9%)
|
292.24M
est: 673.02M (-56.6%)
|
763.68M
763.68M – 763.68M
+13.5% YoY
|
3.45B
3.45B – 3.45B
+351.7% YoY
|
| EPS |
-1.22
est: -0.68 (-80.2%)
|
-0.44
est: 0.06 (-842.1%)
|
-0.85
est: -0.28 (-203.6%)
|
-2.42
est: -0.82 (-195.3%)
|
-1.61
est: -1.35 (-18.8%)
|
-1.63
est: -1.01 (-61.4%)
|
-0.93
est: -0.65 (-43.1%)
|
-0.26
-0.26 – -0.26
+60.1% YoY
|
0.06
0.06 – 0.06
+122.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 41.3K | 0.65% |
| 2 | State Street SPDR S&P China ETF GXC | 0.00% | 1.0K | 0.59% |
| 3 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.00% | 171.76 | 0.42% |
| 4 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 6.2K | 0.33% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hou-Sen Lim MEng. | GM & Executive Director | 3M | male |
| Meirong Liu | VP, Chief Operation Officer & Executive Director | 3M | female |
| Liqiao Ma | Executive Director | 2M | male |
| Joyce Heo | Director of Sales | — | — |
| Renzheng Ma | VP & Chief Technology Officer | — | male |
| Shakeel Osman | Head of International Congenital Heart Disease Business | — | — |
| Wai Chiu Wong | Company Secretary | — | male |
| Yan Xiao | Secretary of the Board | — | female |
| Amir Gross | Head of Venus Global Heart Valve Innovation Center | — | male |
| Zhu Bing | Chief Financial Officer | — | male |
| Bing Zhu | Chief Financial Officer | — | male |
| Christopher Lee Richardson | Head of U.S. Operations | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2500.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
